Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tolerance study of cabozantinib in hepatocellular carcinoma
2019-001142-18Phase 4Completed
- Sponsor
- Hospices Civils de Lyon
- Start
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of cabozantinib in hepatocellular carcinoma (HCC), sponsored by Hospices Civils de Lyon. Primary endpoint: Incidence of treatment-emergent adverse events of interest. Started Mar 2019; status: completed.
02
Drugs
cabozantinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2019-001142-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001142-18.